Huangming Hong

University of Electronic Science and Technology of China (UESTC) - School of Medicine

SCHOLARLY PAPERS

2

DOWNLOADS

77

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Notch Pathway Defines an Aggressive and Immune-Suppressive Phenotype Associated with Checkpoint Inhibitor Resistance in Pan-Gastrointestinal Adenocarcinomas

Number of pages: 33 Posted: 20 Jul 2022
Sichuan Cancer Hospital - Department of Medical Oncology, Burning Rock Biotech, Fudan University - Endoscopy Center and Endoscopy Research Institute, Sichuan Cancer Hospital, University of Electronic Science and Technology of China (UESTC), University of Electronic Science and Technology of China (UESTC) - School of Medicine, Sichuan Cancer Hospital, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), University of Electronic Science and Technology of China (UESTC) - School of Medicine and Sichuan Cancer Hospital - Department of Medical Oncology
Downloads 40 (934,536)

Abstract:

Loading...

Notch pathway, gastrointestinal adenocarcinoma, prognostication, ICI resistance

2.

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients With Metastatic Breast Cancer After First-Line Chemotherapy

Number of pages: 35 Posted: 27 Jan 2021
Sun Yat-Sen University (SYSU), Zhongshan School of Medicine, Sun Yat-Sen Memorial Hospital, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, University of Electronic Science and Technology of China (UESTC) - School of Medicine, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Sun Yat-sen University (SYSU) - Guangdong Key Laboratory of Liver Disease Research, First People’s Hospital of Foshan, Foshan Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Sun Yat-sen University (SYSU) - Department of Ultrasound, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University (SYSU) - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Government of the People's Republic of China - Department of Breast Cancer, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine and Sun Yat-sen University (SYSU) - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation
Downloads 37 (963,863)

Abstract:

Loading...

Metastatic breast cancer; Chemotherapy maintenance; Endocrine therapy maintenance; 57 Overall survival; Progression-free survival